Genetics and Molecular Research · 2016 · 30 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyApoptosis ResistanceCancer Cell SignalingCancer ProgressionCytotoxic ChemotherapyKidney CancerRenal Cell CarcinomaAnti-proliferative SignalingCancer Cell Proliferation InhibitionCancer Signaling PathwaysCell Cycle InhibitionExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase SignalingFlow Cytometric AnalysisMitogen-activated Protein Kinase Signaling
Tremendous efforts have been made in renal cell carcinoma (RCC) patients' research; however, clinical findings in patients have been disappointing. The aims of our study were to identify better or alternative therapeutic methods that can reverse chemotherapy resistance and to enhance sensitivity to docetaxel (DOX)-based chemotherapy drugs. We evaluated the anti-proliferative effect of DOX against RCC cells. DOX was found to suppress proliferation of RCC cells under in vitro and in vivo settings. Flow cytometric analysis revealed that DOX suppressed cell growth by induction of both apoptosis and G2/M cell cycle arrest in a dose-dependent manner. Various patterns of gene expression were observed by cluster analysis. In addition, based on network analysis using the ingenuity pathway analysis software, DOX was found to suppress phosphorylation of extracellular signal-regulated kinase 1/2 and p38, suggesting that the mitogen-activated protein kinase signaling pathway plays a vital role in the anti-proliferative effect of DOX against RCC.
24
MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma.
David A. Brown, Robyn L. Ward, Philip Buckhaults et al. · PubMed · 2003 · 268 citations
Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.
Hong Yang, Zoran Filipovic, David A. Brown et al. · PubMed · 2003 · 161 citations
Medicine, Cancer Biology, Oncology +16
Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer
David A. Brown, Fredrik Lindmark, Pär Stattin et al. · Clinical Cancer Research · 2009 · 147 citations · Full text